Dr Lal PathLabs vs Metropolis Healthcare: Share Price, PE and ROE Compared

August 13, 2026
Posted by: Ankit Jaiswal
Category: advisory

Dr Lal PathLabs MCap Rs 32,723 Cr, PE 59.90x, ROE 20.13%, Div 1.05%. Metropolis Healthcare MCap Rs 11,453 Cr, PE 56.47x, ROE 12.56%.

Quick Answer

Dr Lal PathLabs and Metropolis Healthcare are both listed diagnostics chains. Dr Lal at Rs 32,723 Cr is about 3 times larger with a higher ROE of 20.13% at PE 59.90x. Metropolis at Rs 11,453 Cr trades at PE 56.47x with ROE 12.56%. Both pay modest dividends. Dr Lal’s North India leadership versus Metropolis’s South and West India focus shapes their geographic strategies.

The Dr Lal PathLabs vs Metropolis Healthcare question comes up often among investors who follow the Diagnostics and pathology space in India. Dr Lal PathLabs MCap Rs 32,723 Cr, PE 59. 90x, ROE 20. This article goes through what each company does, their latest financial performance, and the key numbers that matter for anyone evaluating Dr Lal PathLabs vs Metropolis Healthcare as a research exercise.

All data cited here is sourced from publicly available company filings. Verify the latest prices and fundamentals on NSE or BSE before acting on any information.

Table of Contents

Dr Lal PathLabs vs Metropolis Healthcare: Company Overview and Market Presence

Dr Lal PathLabs operates in the Diagnostics and pathology segment and is listed on Indian exchanges. Dr Lal PathLabs MCap Rs 32,723 Cr, PE 59 The company has built its market position over the years through its core offerings to customers across India.

Click Here – Get Free Investment Predictions

Metropolis Healthcare is the other side of this Dr Lal PathLabs vs Metropolis Healthcare comparison. 90x, ROE 20 It competes in the same Diagnostics and pathology space, though its scale and strategy may differ significantly from Dr Lal PathLabs’s approach.

When investors look at the Dr Lal PathLabs vs Metropolis Healthcare pair, market capitalisation is usually the first filter. Dr Lal PathLabs MCap Rs 32,723 Cr, PE 59. 90x, ROE 20. The size difference, if any, tells you something about liquidity and institutional ownership patterns.

Dr Lal PathLabs vs Metropolis Healthcare: Business Mix and Revenue Sources

To understand the Dr Lal PathLabs vs Metropolis Healthcare comparison fully, you need to look at how each company makes money. Dr Lal PathLabs’s revenue comes from its core Diagnostics and pathology operations. Dr Lal PathLabs earns from the Diagnostics and pathology segment.

Metropolis Healthcare similarly derives its earnings from the Diagnostics and pathology space. Metropolis Healthcare operates in the Diagnostics and pathology space. The product or service mix of the two companies can be similar or quite different depending on which subsegments each one serves.

Dr Lal PathLabs vs Metropolis Healthcare: Financial Results and Key Ratios

This is where the Dr Lal PathLabs vs Metropolis Healthcare comparison gets concrete. Return on equity, price-to-earnings ratio and market capitalisation are three metrics that help frame the relative position of each stock.

Dr Lal PathLabs MCap Rs 32,723 Cr, PE 59 The profitability and efficiency ratios here reflect the latest available data from public filings.

90x, ROE 20 Both sets of numbers should be cross-checked against the latest quarterly reports from BSE or NSE before drawing any conclusions.

Compare Dr Lal PathLabs and Metropolis Healthcare on the Univest Screener

Dr Lal PathLabs vs Metropolis Healthcare: Valuation and What the Market Is Pricing In

Valuation is a core part of any Dr Lal PathLabs vs Metropolis Healthcare analysis. A high PE ratio can signal growth expectations or thin earnings. A low PE may indicate value or a business under stress. Neither is automatically good or bad without context.

Dr Lal PathLabs MCap Rs 32,723 Cr, PE 59.90x, ROE 20.13%, Div 1.05%. Metropolis Healthcare MCap Rs 11,453 Cr, PE 56.47x, ROE 12.56%. The Dr Lal PathLabs vs Metropolis Healthcare stock data above reflects figures sourced from publicly available data. Prices change daily, so treat this as a starting point for your own research rather than a definitive trading signal.

Dividend yield is another data point worth checking in the Dr Lal PathLabs vs Metropolis Healthcare pair. Some investors prioritise income alongside capital appreciation, and a consistent dividend track record can be a sign of earnings quality and management confidence in the cash flow.

Dr Lal PathLabs vs Metropolis Healthcare: Side-by-Side Comparison

The table below captures the most relevant metrics side by side for the Dr Lal PathLabs vs Metropolis Healthcare comparison.

Parameter	Dr Lal PathLabs	Metropolis Healthcare
MCap	Rs 32,723 Cr	Rs 11,453 Cr
PE	59.90x	56.47x
ROE	20.13%	12.56%
Div	1.05%	0.91%

What Should Investors Know About the Dr Lal PathLabs vs Metropolis Healthcare Choice

Every Dr Lal PathLabs vs Metropolis Healthcare research exercise should go beyond just looking at the current share price. The sector outlook for Diagnostics and pathology companies, the trajectory of earnings growth, debt levels and management quality all feed into a complete picture.

For the Dr Lal PathLabs vs Metropolis Healthcare pair specifically: Dr Lal PathLabs MCap Rs 32,723 Cr, PE 59. 90x, ROE 20. These numbers are a starting point. Investors should also look at the trend over four to eight quarters rather than just the latest standalone figure, since one strong quarter does not always reflect the underlying business quality.

If you are building a portfolio allocation decision around the Dr Lal PathLabs vs Metropolis Healthcare comparison, consider the risk profile of your overall portfolio first. Both companies operate in Diagnostics and pathology, which carries its own sector-specific risks including regulatory changes, commodity cost pressure, competitive intensity and macroeconomic sensitivity.

Conclusion

The Dr Lal PathLabs vs Metropolis Healthcare comparison comes down to this: Dr Lal PathLabs and Metropolis Healthcare are both listed Indian companies in the Diagnostics and pathology space, but they differ in scale, valuation, and financial profile. Dr Lal PathLabs MCap Rs 32,723 Cr, PE 59. 90x, ROE 20.

Dr Lal PathLabs MCap Rs 32,723 Cr, PE 59.90x, ROE 20.13%, Div 1.05%. Metropolis Healthcare MCap Rs 11,453 Cr, PE 56.47x, ROE 12.56%. Before taking any position in either stock, verify the latest fundamentals on NSE or BSE and consult a SEBI-registered investment advisor (registration number INH000013776).

Download the Univest iOS App or Univest Android App to track Dr Lal PathLabs and Metropolis Healthcare live and get analyst-backed stock recommendations every day.

Disclaimer: Data and figures in this article are sourced from publicly available information and may not be fully accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice from Univest (SEBI RA INH000013776).

Frequently Asked Questions

What does Dr Lal PathLabs do?

Ans. Dr Lal PathLabs is a listed Indian company in the Diagnostics and pathology segment. For the latest business updates, visit univest.in.

What does Metropolis Healthcare do?

Ans. Metropolis Healthcare is a listed Indian company in the Diagnostics and pathology segment. For the latest business updates, visit univest.in.

Which is larger in the Dr Lal PathLabs vs Metropolis Healthcare comparison?

Ans. Based on current market cap data: Dr Lal PathLabs MCap Rs 32,723 Cr, PE 59. Verify the latest figures on NSE or BSE.

How do PE ratios compare in Dr Lal PathLabs vs Metropolis Healthcare?

Ans. The PE ratio comparison is covered in the data table above. Verify current figures from NSE or BSE before investing.

What is the ROE of Dr Lal PathLabs?

Ans. The ROE of Dr Lal PathLabs is mentioned in the data table above. Verify from the latest quarterly filings.

Does Metropolis Healthcare pay dividends?

Ans. Dividend yield information for Metropolis Healthcare is included in the comparison above. Verify from NSE or BSE.

How should I evaluate Diagnostics and pathology stocks?

Ans. For Diagnostics and pathology stocks, review earnings quality, ROE trends, debt levels and sector outlook. Consult a SEBI-registered advisor (INH000013776) before investing.

News

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.